Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Ava Ferguson Bryan, MD, AM, Elizabeth Yates, MD, MPH, and Neelima Tummala, MD, MSc
The health sector has obligations and ample opportunities to protect health by decreasing waste and motivating more system-wide sustainable clinical practices.
AMA J Ethics. 2022;24(10):E927-933. doi:
10.1001/amajethics.2022.927.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”
Dr Mustfa K. Manzur joins Ethics Talk to discuss his article, coauthored with Drs Sharon Griswold and Wendy Dean: "What Should Clinicians Do When Health Services Are Improperly Billed in Their Names?"
Dr Christopher Whaley joins Ethics Talk to discuss his article, coauthored with Dr Austin Frakt: “If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important?”